CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M

CVRx, Inc.

2022-FY EPS reported -$4.16 revenue$13,036,000

Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.
Full year 2021 revenue $13.0M, up 115% YoY; net loss $43.1M ($4.16 per share).
Guides FY2022 total revenue $20-23M; Q1 2022 revenue $3.6-4.0M; gross margin 74-76%.
Received FDA approval for new IPG in Dec 2021; expects MRI labeling and new programmer approvals in H1 2022.
Fully repaid $20M loan in Nov 2021; cash $142.1M at year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.